ZIP (SCRAMBLED)
(Synonyms: 加扰控制肽,z-Pseudosubstrate inhibitory peptide) 目录号 : GC13461
ZIP (SCRAMBLED) 是 zeta 抑制肽 (ZIP) 的乱序对照肽。
Cas No.:908012-18-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: By suppressing protein kinase Mξ (PKMξ), ZIP reverses late-phase LTP with an IC50 of 1 - 2.5 μM.
Long-term potentiation (LTP), a persistent synaptic enhancement, is considered to be a substrate for memory. A typical LTP process includes two phases, induction and maintenance. PKMξ as an active form of protein kinase C (PKC) isozyme is necessary and potent for LTP maintenance. ZIP is applied as a novel and cell-permeable inhibitor for PKMξ and can therefore block LTP. [1]
In vitro: In order to determine the specific phase of LTP affected by PKMξ, ZIP was added at different concentrations to the bath before cells incubation. Experiments with ZIP were compared with experiments without the peptide. This study showed that ZIP could selectively inhibit PKMξ-induced synaptic potentiation in hippocampal slices in vitro. [2]
In vivo: ZIP was the first tool available to test the maintenance hypothesis in vitro. The effect of ZIP on late phase of LTP in vivo was also detected using the rat hippocampus. It was found that intra-hippocampal injection of ZIP with a dosage of 10 nmol in 1 ml saline rapidly reversed the late-phase LTP and led to persistent loss of 1-day-old spatial memory. [3]
Clinical trial: So far, no clinical trial has been conducted.
References:
[1]Ling SF, Benardo LS, Serrano PA, Blace N, Kelly MT, Crary JF and Sacktor TC. Protein kinase Mξ is necessary and sufficient for LTP maintenance. Nat. Neurosci. 2002 Apr. 5(4): 2956.
[2]Serrano P, Yao Y and Sacktor TC. Persistent phosphorylation by protein kinase maintains late-phase long-term potentiation. J. Neurosci. 2005 Feb. 25(8): 1979–84.
[3]Pastalkova E, Serrano P, Pinkhasova D, Wallace E, Fenton AA, Sacktor TC. Storage of spatial information by the maintenance mechanism of LTP. Science. 2006 Aug. 313: 1141-4.
| Cas No. | 908012-18-0 | SDF | |
| 别名 | 加扰控制肽,z-Pseudosubstrate inhibitory peptide | ||
| 分子式 | C90H154N30O17 | 分子量 | 1928.4 |
| 溶解度 | ≥ 192.8mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5186 mL | 2.5928 mL | 5.1856 mL |
| 5 mM | 0.1037 mL | 0.5186 mL | 1.0371 mL |
| 10 mM | 0.0519 mL | 0.2593 mL | 0.5186 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。